(S)-3-(4-azidobutanoyl)-4-benzyloxazolidin-2-one | 1104195-17-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (S)-3-(4-azidobutanoyl)-4-benzyloxazolidin-2-one
• 英文别名: (4S)-3-(4-azidobutanoyl)-4-benzyl-1,3-oxazolidin-2-one
• CAS: 1104195-17-6
• 化学式: C₁₄H₁₆N₄O₃
• 分子量: 288.306
• InChiKey: SOMOSMJAHBOCTH-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  61
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-3-(4-azidobutanoyl)-4-benzyloxazolidin-2-one 在 咪唑 、 甲醇 、 4-二甲氨基吡啶 、 sodium hexafluoroantimonate 、 三氟乙酸 、 magnesium chloride 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.17h， 生成 (S)-3-((2R,3R,E)-2-(2-azidoethyl)-3-((tert-butyldimethylsilyl)oxy)-5-phenylpent-4-enoyl)-4-benzyloxazolidin-2-one
  参考文献：
  名称：

  实用的对映选择性合成（3 S，4 R）-3-羟基哌啶-4-羧酸

  摘要：

  （3S，4R）-3-羟基哌啶-4-羧酸的实际对映选择性合成是通过非常规的Evans抗-醛醇缩合反应，随后是一锅叠氮化物还原/还原环化而完成的。

  DOI：

  10.1016/j.tetlet.2019.04.023
• 作为产物：
  描述：

  (S)-4-苄基-2-唑烷酮 在 正丁基锂 、 sodium azide 作用下， 以 四氢呋喃 、 正己烷 、 水 、 丙酮 为溶剂， 反应 74.5h， 生成 (S)-3-(4-azidobutanoyl)-4-benzyloxazolidin-2-one
  参考文献：
  名称：

  Conjugates of Modified Cryptophycins and RGD-Peptides Enter Target Cells by Endocytosis

  摘要：

  Tumor targeting anticancer drug conjugates that contain a tumor recognition motif (homing device) are of high current relevance. Cryptophycins, naturally occurring cytotoxic cyclo-depsipeptides, have been modified by total synthesis to provide analogues suitable for conjugation to peptide-based homing devices. An array of functionalized beta(2)-amino acids was synthesized and incorporated into cryptophycins. All analogues proved to be highly active in the cytotoxicity assay using the human cervix carcinoma cell line KB-3-1 and its multidrug-resistant subclone KB-V1. Conformational analysis of cryptophycin-52 and two synthetic analogues was performed by NMR and MD methods to obtain information on the influence of the unit C configuration on the overall conformation. An azide-functionalized cryptophycin was connected by CuAAC to an alkyne-containing fluorescently labeled cyclic RGD-peptide as the homing device for internalization studies. Confocal fluorescence microscopy proved integrin-mediated internalization by endocytosis and final lysosomal localization of the cryptophycin prodrug.

  DOI：

  10.1021/jm301346z

文献信息

• [EN] MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS<br/>[FR] DÉRIVÉS MACROCYCLIQUES D'INDOLE POUR LE TRAITEMENT DES INFECTIONS D'HÉPATITE C
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2009010783A1

  公开（公告）日：2009-01-22

  A class of macrocyclic compounds of formula (I), wherein R7, R9, B, F, M, Q, W, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such 5 macrocyclic compounds for treating or preventing HCV infection.

  提供一类宏环化合物的化学式(I)，其中R7、R9、B、F、M、Q、W、Y和Z的定义如下，这些化合物可用作病毒蛋白酶抑制剂，特别是对乙型肝炎病毒（HCV）NS3蛋白酶的抑制剂。还提供了合成和使用这些5种宏环化合物的方法，用于治疗或预防HCV感染。
• [EN] MACROCYCLIC AND 7-AMINOALKYL-SUBSTITUTED BENZOXAZOCINES FOR TREATMENT OF HEPATITIS C INFECTIONS<br/>[FR] COMPOSÉS BENZOXAZOCINES SUBSTITUÉS 7-AMINOALKYLE MACROCYCYCLIQUES DESTINÉS AU TRAITEMENT DES INFECTIONS PAR HÉPATITE C
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2010082050A1

  公开（公告）日：2010-07-22

  The present invention provides a compound of formula (I), wherein R1 is selected from hydrogen, hydroxyl, fluoro or a C1-4alkoxy group or R1 is linked to R3 to form a 4, 5 or 6-membered aliphatic ring optionally containing one N or O atom; R2 is selected from cyclopentyl or cyclohexyl optionally substituted by a fluoro; R3 is hydrogen or is linked to R1 as hereinbeforedefined; R4 is hydrogen, a C1-4alkyl group optionally substituted by a group NR8R9 in which R8 and R9 are each hydrogen or a C1-4alkyl group or R4 is linked to R6 to form a (CH2)mNR10SO2N group wherein m is an integer selected from 2 or 3 and R10 is a C1-4 alkyl group; R5 is hydrogen or a C1-4 alkyl group; R6 is hydroxyl or is linked to R4 as hereinbefore defined; R7 is hydrogen or an aliphatic ring of 4-7 ring atoms containing one or two heteroatoms selected from O, N or S or a group S(O), S(O)2,NH or NC1-4alkyl and optionally substituted by fluoro or R7 is a 5- 10-membered heteroaromatic ring system containing 1 to 4 heteroatoms independently selected from N, O and S, which ring is optionally substituted by one or two halo atoms or C1-4alkyl or C1-4alkoxy groups; Y is a single bond or a CH2 group; when R4 is linked to R6 and m is 3 then Y is a single bond; when R4 is linked to R6 and m is 2 then Y is a CH2 group; n is an integer from zero to four, with the proviso that when R1 is hydrogen, n is not zero; or a pharmaceutically acceptable salt thereof, pharmaceutical formulations containing it and its use in medicine, particularly for the treatment of HCV infections. Hepatitis C (HCV) is a cause of viral infections. Methods of preparing compounds of the formula (I) arc also disclosed.

  本发明提供了一种化合物，其化学式为(I)，其中R1选自氢、羟基、氟或C1-4烷氧基，或者R1与R3连接形成一个含有一个N或O原子的4、5或6元脂环；R2选自环戊基或环己基，可以选择地被氟取代；R3为氢或与上述定义的R1连接；R4为氢，一个C1-4烷基，可以选择地被NR8R9基团取代，其中R8和R9分别为氢或C1-4烷基，或者R4与R6连接形成(CH2)mNR10SO2N基团，其中m为2或3的整数，R10为C1-4烷基；R5为氢或C1-4烷基；R6为羟基或与上述定义的R4连接；R7为氢或含有一个或两个来自O、N或S的杂原子的4-7环原子的脂环，或者为S(O)、S(O)2、NH或NC1-4烷基基团，可以选择地被氟取代，或者R7为含有1至4个来自N、O和S的杂原子的5-10元杂芳环系统，该环可以选择地被一个或两个卤原子或C1-4烷基或C1-4烷氧基取代；Y为单键或CH2基团；当R4与R6连接且m为3时，Y为单键；当R4与R6连接且m为2时，Y为CH2基团；n为0到4的整数，但当R1为氢时，n不为零；或其药学上可接受的盐，包含它的药物制剂以及其在医学上的应用，特别是用于治疗丙型肝炎（HCV）感染。丙型肝炎（HCV）是病毒感染的原因。还公开了制备化合物(I)的方法。
• Therapeutic compounds
  申请人：Conte Immacolata

  公开号：US20090048239A1

  公开（公告）日：2009-02-19

  A class of macrocyclic compounds of formula (I), wherein R 7 , A, Ar, B, D, F, M, Q 1 , Q 2 , W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.

  提供一类宏环化合物(I)的公式，其中R7、A、Ar、B、D、F、M、Q1、Q2、W、X、Y和Z在此定义，可用作病毒蛋白酶的抑制剂，特别是乙型肝炎病毒（HCV）NS3蛋白酶的抑制剂。同时提供了合成和使用这种宏环化合物治疗或预防HCV感染的方法。
• MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS
  申请人：Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.

  公开号：EP2178885A1

  公开（公告）日：2010-04-28
• US7989438B2
  申请人：——

  公开号：US7989438B2

  公开（公告）日：2011-08-02